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Inhibitor developmentThe alarming increase of drug resistance in Mycobacterium tuberculosis strains poses a severe threat to human
health. Chemotherapy is particularly challenging because M. tuberculosis can persist in the lungs of infected
individuals; estimates of the WHO indicate that about 1/3 of the world population is infected with latent tuber-
culosis providing a large reservoir for relapse and subsequent spread of the disease. PersistentM. tuberculosis
shows considerable tolerance towards conventional antibiotics making treatment particularly difﬁcult. In
this phase the bacilli are exposed to oxygen and nitrogen radicals generated as part of the host response
and redox-defense mechanisms are thus vital for the survival of the pathogen. Sulfur metabolism and de novo
cysteine biosynthesis have been shown to be important for the redox homeostasis in persistentM. tuberculosis
and these pathways could provide promising targets for novel antibiotics for the treatment of the latent form
of the disease. Recent research has provided evidence for three de novometabolic routes of cysteine biosynthesis
inM. tuberculosis, eachwith a speciﬁc PLP dependent cysteine synthasewith distinct substrate speciﬁcities. In this
reviewwe summarize our present understanding of these pathways, with a focus on the advances on functional
and mechanistic characterization of mycobacterial PLP dependent cysteine synthases, their role in the various
pathways to cysteine, and ﬁrst attempts to develop speciﬁc inhibitors of mycobacterial cysteine biosynthesis.
This article is part of a Special Issue entitled: Cofactor-dependent proteins: evolution, chemical diversity and
bio-applications.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Introduction
Mycobacterium tuberculosis and modern humans share a long
coevolutionary history, reaching back to about 70,000 years ago [1].
Unfortunately this common history still continues and, in spite
of the availability of chemotherapy, the pathogen causes about 2
million deaths per year (http://www.who.int/tb/en/). The emergence
of M. tuberculosis strains resistant to most ﬁrst line defense drugs and
of totally drug resistant strains [2] threatens to reverse the advances
in the treatment of tuberculosis made in the last century and poses a
severe challenge to human health.
In the initial stages of tuberculosis, infectedmacrophages will release
cytokines that lead to the recruitment of immune cells, for instanceine; PLP, pyridoxal-5-phosphate,
lationships
-dependent proteins: evolution,
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.
. This is an open access article underneutrophils, macrophages, NK cells and T cells to form granuloma.
These are structures within the infected tissue, with bacilli-containing
macrophages at the center surrounded by other immune cells such as
B and T lymphocytes, non-infected macrophages and ﬁbroblasts [3].
The function of the granuloma is not quite clear, but it has been sug-
gested that they contain the bacilli and thus prevent their uncontrolled
spread.Within the granuloma,M. tuberculosis is exposed to environmen-
tal stress conditions, thought to include hypoxia, nutrient depletion and
oxidative stress [4]. Under these conditions mycobacteria can enter a
persistent phase, characterized by a lack of (or very slow) cell division
and substantial changes in metabolism [5]. At this stage the infection is
non-contagious and no symptoms are observed. Present estimates of
the WHO indicate that about 1/3 of the world population is infected
with latent tuberculosis, providing a large reservoir for relapse and
subsequent spread of the disease. Treatment of latent tuberculosis is
very difﬁcult, if at all possible, because persistentM. tuberculosis shows
considerable tolerance towards conventional antibiotics [6].
Not least in view of the challenges in chemotherapy of tuberculosis
and the alarming increase of antibiotic resistance in M. tuberculosis,
the elucidation of the regulatorymechanisms for the switch from actively
dividing to persistent bacteria, aswell as themetabolic processes essentialthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. The three cysteine synthases encoded in the genome ofM. tuberculosis.
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Persistent bacilli are exposed to reactive oxygen (ROI) and reactive ni-
trogen (RNI) intermediates generated as a part of the host response [7].
Redox-defense mechanisms are thus vital for the survival of the patho-
gen and related pathways are consistently found to be up-regulated
in persisters [5,8,9]. An important metabolite in the redox-defense of
M. tuberculosis is mycothiol, found in millimolar concentration in the
cell [10–12]. This compound contains a cysteine-derived sulfhydryl
group as active moiety [13] and its biosynthesis requires the availability
of cysteine. Also other molecules involved in the defense against oxida-
tive stress in M. tuberculosis such as thioredoxins rely on a supply ofFig. 2. Structural enzymology of cysteine biosynthesis inM. tuberculosis. A: Cartoon of the three
dark blue and the C-terminal domain by helices in lighter blue color. The PLP cofactor is shown
mation of the α-aminoacrylate intermediate in CysK1. The open form of the enzyme is shown
active site closure. C: Surface viewof the CysK1-aminoacrylate complex, showing the narrow ch
the three-dimensional structure of CysM, with the N-terminal and C-terminal domains shown
the open (red) and closed (blue) form of CysM [17,28]. The C-terminal residues, which insert
CysM–CysO complex [16]. CysM is shown in green and CysO in orange. The position of the C-tcysteine, underpinning cysteine biosynthesis as an important cellular
process in maintaining redox homeostasis in this pathogen.
Research during the last decade has painted a rather complex
picture of the de novo biosynthesis of cysteine in M. tuberculosis. In
this review we will summarize our present understanding of these
pathways, with a focus on the mycobacterial pyridoxal-5-phosphate
(PLP) dependent cysteine synthases. A previous review [14] highlighted
the insights obtained from structural studies of enzymes from sulfur
metabolism. Here we focus on the advances on functional and mecha-
nistic characterization of these enzymes, in particular the role of PLP
dependent cysteine synthases in the various pathways to cysteine, and
ﬁrst attempts to develop speciﬁc inhibitors.
2. The de novo cysteine biosynthetic pathways inM. tuberculosis
2.1. The M. tuberculosis genome encodes three cysteine synthases
The genome ofM. tuberculosis H37Rv contains three genes that had
been annotated to encode putative O-acetylserine sulfhydrylases,
Rv2334, Rv0848 and Rv1336. The corresponding proteins are denoted
CysK1, CysK2 and CysM (Fig. 1). The three proteins are related in
amino acid sequence, with CysK1 and CysM displaying 37% sequence
identity. CysK2 is more distantly related to the other two enzymes,
with only about 26% identity to CysK1 and CysM, respectively. Unfortu-
nately the nomenclature of cysteine synthases varies between different
organisms and is confusing. Most bacteria contain two cysteine
synthases, usually denoted OASS A (or CysK) and OASS B (or CysM).
Inmycobacteria, OASS A is denoted CysK1,whereas OASS B corresponds
to CysK2. Mycobacterial CysM is rather unique in its properties and is
only found in actinobacteria, including Mycobacteria, Streptomyces
and Corynebacteria. In the following we shall use the mycobacterial
naming convention unless stated otherwise.-dimensional structure of CysK1 [15]. The N-terminal domain is indicated by α-helices in
as stick model. B: Conformational changes leading to partial active site closure upon for-
in blue, and the closed form in red. The arrows indicate the domain movement leading to
annel leading to the Cβ carbon atomof the intermediate, indicated in yellow. D: Cartoon of
in light and dark green, respectively. PLP is shown as a stick model. E: Superposition of
into the active site cleft in the closed form, are highlighted by an arrow. F: Cartoon of the
erminus of CysO, carrying the thiocarboxylate, is indicated by a red sphere.
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The three-dimensional structures of CysK1 and CysM have been
determined by X-ray crystallography [15–17] (Fig. 2). They show the
typical fold of the type II class of PLP-dependent enzymes [18]. The
three-dimensional structure of CysK2 has not been determined yet,
but the degree of amino acid sequence identity of CysK2 to the other
two cysteine synthases and the presence of conserved sequence motifs
suggest that this enzyme belongs to the same fold class [19]. The
enzymes are homo-dimers, both in solution and in the crystal. Each
subunit consists of two domains and the PLP binding site is formed in
a cleft between the C-terminal ends of the β-sheets of the two domains
within one subunit (Fig. 2A).While the overall fold of CysK1 is identical
to that of CysM there are signiﬁcant differences in primary and tertiary
structures of the active site loops, which are related to differences in
substrate speciﬁcities and stabilization of the aminoacrylate intermedi-
ate (see below).
2.3. CysK1 is a PLP dependent O-acetylserine sulfhydrylase
Mycobacterial CysK1 is a bona ﬁde PLP dependent O-acetylserine
sulfhydrylase, which converts O-acetylserine and sulﬁde to cysteine [15]
. The enzymemechanism involves two half reactions as described for ho-
mologous enzymes (Scheme 1) [20]. OAS forms an external aldimine
with the PLP cofactorwhich is converted throughβ-elimination of acetate
into the central α-aminoacrylate intermediate. In the second half of this
reaction a nucleophilic attack of sulﬁde onto this intermediate leads to
the formation of cysteine.
The structure of the enzyme–α-aminoacrylate complex could be
determined using cryo-crystallographic methods [15]. Formation ofScheme 1. Catalytic cycle of CysK1 fromM. tuberculosis. In the ground state the PLP cofactor for
O-acetylserine (OAS) results in an external aldimine. Elimination of acetate and deprotonation of t
the catalytic cycles of cysteine synthases. In the second half-reactionnucleophilic attack by sulﬁde o
in formation of L-cysteine [15]. The catalytic cycles of CysM and CysK2 are different as O-phophos
ﬁrst half-reaction, leading to the aminoacrylate intermediate. In the second half-reaction CysM us
protein CysO [26]. CysK2 can react with sulﬁde and produce L-cysteine; however it preferentiallythis intermediate is associated with a large conformational change, i.e.
a rotation of the domains of the enzyme subunit resulting in partial
closure of the active site cleft (Fig. 2B and C).
In plants and many bacteria, cysteine biosynthesis by the bona ﬁde
O-acetylserine sulfhydrylase is subject to a subtle regulation [21,22]
(Fig. 3). In the presence of the acceptor substrate OAS CysK1 is active
and converts OAS to cysteine. Upon depletion of OAS, CysK1 forms a
complexwith the preceding enzyme of the pathway, serine acetyltrans-
ferase (CysE), leading to inhibition of CysK1. In the complex CysE is
active and produces OAS from serine and acetyl-CoA. Increasing OAS
concentrations result in dissociation of the complex and active CysK1.
Complex formation involves the insertion of the last C-terminal residues
of CysE into the active site cleft of CysK1 [23–25]. This regulatory mech-
anism also holds for mycobacterial CysK1. A peptide comprising the
last four C-terminal residues (Asp-Phe-Ser-Ile) of mycobacterial CysE
competitively inhibits CysK1with a Ki of 5.0 μM. The structure determi-
nation by X-ray crystallography of the enzyme-peptide complex
revealed binding of this peptide in the active site cleft of CysK1 [15]
(Fig. 3).
2.4. CysM is a O-phosphoserine dependent cysteine synthase
CysM had been annotated as an OAS sulfhydrylase, but no cysteine
formation comparable to CysK1 driven catalysis could be detected
using OAS and sulﬁde. A key step forward in the understanding of the
mechanism and function of this enzyme was the discovery that CysM
uses a small sulfur delivery protein, CysO, which is thiocarboxylated at
the C-terminus, as the sulfur donor—an unprecedented reaction in cys-
teine biosynthesis [26]. Subsequent work by us [17] and Begley et al.
[27] demonstrated that not OAS, but OPS is the preferred acceptorms a Schiff-base with an invariant lysine residue, Lys44. Addition of the acceptor substrate
he C-α atom of the substrate by Lys44 lead to theα-aminoacrylate intermediate common to
n the C-β carbon atomof the intermediate and re-protonation of the C-α carbon atom results
erine is utilized as substrate. Consequently phosphate rather than acetate is eliminated in the
es a unique sulfur-donor, the thiocarboxylated carboxy terminus of the small sulfur-delivery
uses thiosulfate in the sulfur addition step leading to S-sulfocysteine [19].
Fig. 3. Schematic view of the regulatory interplay between the serine-acetyl transferase
CysE and the O-acetyl sulfhydrylase CysK1 in cysteine biosynthesis. Complex formation
is achieved by insertion of the C-terminal residues of CysE (shown in green) into the active
site channel of CysK1. The three-dimensional structure of CysK1, with the bound peptide
comprising the four C-terminal residues of CysE (Asp-Phe-Ser-Ile) is shown at the top.
Accumulation of OAS leads to dissociation of the complex resulting in active CysK1.
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OAS. CysM is thus an OPS dependent cysteine synthase using a
thiocarboxylated protein as sulfur donor. The crystal structure of CysM
(Fig. 2D and E) and the CysM–CysO complex (Fig. 2F) showed that
several loop regions of CysM in the vicinity of the active site undergo
conformational changes upon binding of CysO [16]. The mechanism of
this reaction is unique and differs from that of other cysteine synthases.
The ﬁrst half reaction, formation of the α-aminoacrylate from OPS,
is consistent with themechanism of other cysteine synthases. However,
in the second reaction a nucleophilic attack of CysO-SH on the
aminoacrylate followed by a S,N-acyl shift results in the formation of a
CysO-cysteine adduct, which is subsequently hydrolyzed by the Zn2+
dependent hydrolase Mec+ [26].
A comparison of the structures of CysK1 and CysM suggested an ar-
ginine residue in the active site cleft of CysM as a key feature for the
switch of OAS towards OPS selectivity [17]. Replacement of this residue,
Arg220, by alanine resulted in a loss of OPS preference, i.e. approximate-
ly 600 fold decrease of the reaction ratewith OPS, whereas the ratewith
OAS remained unchanged. Notably, the reaction with the sulfur donor
was not affected by this amino acid replacement, thus conﬁrming the
central role of Arg220 in OPS speciﬁcity of CysM.
In the course of our work we noted a signiﬁcant higher stability of
the CysM–α-aminoacrylate intermediate towards hydrogen peroxide
compared to the corresponding complexes of mycobacterial CysK1
and E. coli CysM [28]. Crystal structures of CysM had revealed an open
conformation, with the bound cofactor accessible from the bulk solu-
tion, and a closed conformation, where two active site loops and the
C-terminal residues fold over the active site making it inaccessible
(Fig. 2E). This conformational change, triggered by a disorder–order
transition of the C-terminus of CysM, most likely is responsible for the
increased stability of the reaction intermediate in this enzyme, becauseit restricts access of reactive oxygen (ROI) or nitrogen (RNI) intermedi-
ates to the active site under oxidative stress conditions. Consistent with
this notion is the ﬁnding that truncation of the last C-terminal residues
of CysM, preventing this conformational change, results in a signiﬁcant
drop in stability of the intermediate [28]. The cysM and cysO genes are
up-regulated in the persistent phase ofM. tuberculosis suggesting that
this pathwaymay be the major route towards cysteine under oxidative
stress. The increased stability and resistance of the reaction intermedi-
ate in CysM catalysis, not observed in other cysteine synthases, would
favor this pathway of cysteine formation under oxidative stress condi-
tions. The use of thiocarboxylated CysO as sulfur donor further favors
this pathway, because thiocarboxylates are more stable than sulﬁde
towards oxidative degradation.
2.5. CysK2 is a sulfocysteine synthase
The role of CysK2 had been rather enigmatic [29] as there were no
functional data available for this enzyme. Although annotated as OAS
sulfhydrylase no such activity could be detected using OAS and sulﬁde
as substrates. Recently we could present biochemical and biophysical
evidence that CysK2 uses O-phosphoserine as acceptor substrate, with
an apparent second-order rate constant for the ﬁrst half reaction of
4 × 103 M−1 s−1, comparable to the OPS dependent CysM. However
CysK2 does not use CysO as sulfur donor but accepts sulﬁde and thio-
sulfate as donor substrates, leading to the formation of cysteine or
sulfocysteine, respectively [19]. The reaction rate with sulﬁde is slower
(kcat = 0.2 s−1) compared to the turnover number with thiosulfate,
kcat = 1 s−1. The speciﬁcity constant kcat/Km for thiosulfate is 40-fold
higher than for sulﬁde suggesting that CysK2 is a sulfocysteine synthase.
2.6. Three de novo pathways to cysteine
Studies of de novo cysteine biosynthesis in M. tuberculosis and the
biochemical characterization of the enzymes involved in this pathway
have revealed a rather complex picture of the biosynthesis of this
amino acid in this pathogen (Fig. 4). The classical pathway based on
the serine acetyltransferase CysE [30] and the bona ﬁde O-acetylserine
sulfhydrylase CysK1, found in plants and bacteria, is also present in
M. tuberculosis. The necessary sulfur donor in the form of sulﬁde is
provided by the reductive branch of the adenosine 5′phosphosulfate
(APS) pathway [31–34].
A second pathway, most likely active under conditions prevailing in
the latent phase of the infection, is deﬁned by the cysteine synthase
CysM and the sulfur carrier protein CysO (Fig. 4). This biosynthetic
route starts from O-phosphoserine, ultimately derived from phospho-
glycerate as acceptor substrate.
CysK2 provides yet a third route to L-cysteine based on OPS and sul-
ﬁde, although the slow turnover of these substrates makes a signiﬁcant
contribution to de novo biosynthesis less likely (Fig. 4). Kinetic parame-
ters of CysK2 show a preference for thiosulfate as sulfur donor, resulting
in the formation of sulfocysteine. This metabolite can be converted into
cysteine by reduction through small thiol-containing proteins such as
thioredoxins as shown for E. coli [35]. Thiosulfate can be formed under
conditions of oxidative stress prevailing in the persistent phase in in-
fected macrophages due to incomplete reduction of sulfate. The CysK2
catalyzed sulfocysteine formation could thus provide a salvage pathway
whereby some of the sulfur is rescued through incorporation into
cysteine. However given the low catalytic performance of CysK2 it is
questionable if this route will make a substantial contribution to cysteine
biosynthesis in vivo. Alternatively, sulfocysteine could act as a signaling
molecule of oxidative stress and trigger appropriate defensemechanisms
in thepathogen [19]. A similar role for sulfocysteine has been suggested in
plants during light induced oxidative stress [36]. M. tuberculosis thus
contains three distinct pathways for the de novo formation of cysteine
and each of these metabolic routes contains a different PLP dependent
cysteine synthase with distinct substrate preferences.
Fig. 4. The pathways of de novo cysteine biosynthesis inM. tuberculosis. Each pathway is characterized by its own cysteine synthase, with speciﬁc substrate preferences. The classical path-
way (red), found also in othermicroorganisms and plants, starts from serine. The sulfur donor HS− is produced by the reductive branch of the APS pathway. The second route to cysteine
(blue) uses OPS as acceptor substrate and the sulfur is provided through the thiocarboxylated CysO, a unique pathway present in actinobacteria includingmycobacteria. A third pathway is
based on CysK2, which can react with HS− as sulfur donor to produce cysteine or with thiosulfate to produce sulfocysteine. The latter can be reduced to cysteine or, alternatively act as a
signaling molecule to trigger an oxidative stress response in the bacterium.
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Cysteine is an essential building block in proteins, and for bacteria
that are internalized in the host macrophages, that impose oxidative
stress as part of the innate immune defense against bacteria, cysteine
is an essential component in the redox defense. Therefore de novo
cysteine biosynthesis has been considered essential for survival of the
pathogen within the host and interference with cysteine biosynthesis
has been proposed as a potential route to the discovery of new antibi-
otics [37]. This approach would be particularly attractive as humans
lack the enzymes from this pathway.
So is there any experimental evidence that de novo cysteine biosyn-
thesis indeed is essential to bacterial pathogens or that inhibitionwould
be disruptive to the life cycle of the bacteria?
First indications come from the observation that cysteine biosynthe-
sis is consistently up-regulated in dormancy models [9,38]. This is
particularly true for persistentM. tuberculosis surviving in infectedmac-
rophages in the granuloma, where it is exposed to hypoxia, nutrient
starvation and oxidative stress through oxygen and nitrogen radicals
produced by the host as part of the immune response. One of the
major metabolites used byM. tuberculosis in the defense against redox
stress is mycothiol, containing a cysteine derived moiety as the active
part of themolecule [12]. Redox-defense is thus linked to the availability
of cysteine, emphasizing the need for de novo biosynthesis of this amino
acid in the persistent phase. Cysteine is also required for the repair of
iron–sulfur center containing proteins, damaged by reactive ROS and
RNI species [8]. Gene-expression proﬁling has shown up-regulation of
genes from sulfur metabolism and cysteine biosynthesis in environmen-
tal conditions usually associated with the persistent phase, including
cysD, cysNC, and sirA from the APS pathway and cysM and cysK2 from
cysteine biosynthesis [8,9,38–40].It could be argued thatM. tuberculosis can incorporate cysteine from
the host and therefore might not be dependent on de novo cysteine
biosynthesis. It has been shown that actively dividing mycobacteria in
cell culture can incorporate cysteine from the medium [41,42], but the
up-regulation of genes related to sulfur metabolism and cysteine
biosynthesis in persisters suggests that in this metabolic state the host
does not supply sufﬁcient amounts of cysteine. The latent phase is char-
acterized by the formation of granuloma, withM. tuberculosis exposed
to environmental stress conditions such oxidative stress and nutrient
depletion. Under these conditions the external supply of cysteine most
likely is limited.
Further evidence for the importance of sulfurmetabolismand cysteine
biosynthesis for the survival ofM. tuberculosis comes from randomized
transposon mutagenesis studies which demonstrated profound effects
for cysD, cysH, cysE, cysNC, cysO and cysM by gene disruption [43]. These
studies have also shown attenuation of cysE, cysO and cysMmutants of
M. tuberculosis in in vitro models of dormancy and of cysO and cysM
mutants in a mouse model of infection [44]. A gene knock-out study of
cysH demonstrated signiﬁcant attenuation of the mutant during the
chronic phase of the infection inmice [41]. Furthermore, a comprehensive
in silico network analysis using proteomics and experimentally derived
phenotype essentiality data from M. tuberculosis suggested CysE and
CysK2 from cysteine biosynthesis as high-conﬁdence drug targets [45].
4. Development of O-acetyl sulfhydrylase inhibitors
Enzymes from sulfur metabolism in M. tuberculosis have attracted
attention as potential drug targets and progress in the development of
inhibitors of sulfurmetabolism has been reviewed [36,46]. In the follow-
ing we will summarize recent efforts towards inhibitor development
against enzymes from mycobacterial cysteine biosynthesis, speciﬁcally
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the homologous CysK from other pathogens.
4.1. Inhibitors of mycobacterial CysK1
In one approach to identify scaffolds for mycobacterial CysK1 in-
hibitors the crystal structure of the enzyme with the inhibitory CysE
peptide (Asp-Phe-Ser-Ile) [15] was used as template for virtual
screening of a small-molecule database [47]. The screen identiﬁed
8-nitro-2-thioxo-4-(2-nitrophenyl)-4,4a-dihydro-2H-pyrimido[5,4-e]
thiazolo[3,2-a]pyrimidin-5(3H)-one as initial hit which inhibited CysK1
in vitro with an IC50 value of 30.3 μM and a MIC (minimum inhibitory
concentration to completely inhibit mycobacterial growth) value of
30.9 μM. Chemical synthesis of a small library of substituted nitro-5H-
thiazolo [3,2-a] pyrimidinones for hit optimization resulted in the
most promising lead 8-nitro-4-(2-(triﬂuoromethyl)phenyl)-4,4a-
dihydro-2H-pyrimido[5,4-e]thiazolo[3,2-a]pyrimidine-2,5(3H)-dione
with an IC50 of 17.7 μM for puriﬁed CysK1 and a MIC of 7.6 μM [47].
For comparison, the MIC value for the ﬁrst line drug isoniazid was
determined to be 0.72 μM under the assay conditions.
A second approach towards design of potent inhibitors of CysK1
also used the enzyme–peptide complex as template. The crystal
structure of this complex was used to derive an energy-based
pharmacophore, which was employed in in silico screening of a com-
mercial data base (Asinex) to identify non-peptidic scaffolds for in-
hibitor design [48]. This approach is shown in more detail in Fig. 5.
The resulting 50 top hits were evaluated experimentally by enzyme
assays, which identiﬁed seven inhibitors, with the thiazolidine com-
pound 3-({5-[2-(carboxymethoxy)benzylidene]-3-methyl-4-oxo-
1,3-thiazolidin-2-ylidene}amino)benzoic acid (Fig. 5) being by farFig. 5. Illustration of the strategy employed for CysK1 hit identiﬁcation using e-pharmacophor
the pose of the bound ligand in the active site and the key interactions of the ligandwith enzym
Important features of the pharmacophore are the hydrophobic substituents and hydrogen ac
process the strongest hit (bottom left) was identiﬁed exhibiting an IC50 of 103 nM.the most potent hit with a IC50 value of 103 nM. The crystal structure
of the complex of this compound with CysK1 was used for improve-
ment of the pharmacophore and further iterative screening. Structure-
based modeling provided the leads for the synthesis of several sub-
libraries for ligand optimization and the derivation of structure–activity
relationships (SAR) (Table 1). The protocol led to the development of
improved CysK1 inhibitors, with an IC50 value of 19 nM for the most
potent molecule, 3-((Z)-((Z)-5-(4-ﬂuorobenzylidene)-3-methyl-4-
oxo-thiazolidin-2-ylidene)amino)benzoic acid (Fig. 6).
Initial SARdata (Fig. 6) demonstrated the importance of the carboxyl
group of the secondary phenyl ring of the scaffold for strong binding.
This carboxyl group binds in the same position as the carboxyl group
of the acceptor substrate OAS [15,48] and interacts with residues of
the conserved 71TSTGNT75 loop of CysK1. Substituents at the nitrogen
atom of the thiazolidine ring point into a pocket of the enzyme,
which prefers small hydrophobic moieties (Fig. 6). Attempts to
substitute the benzylidine ring with other aromatic ring systems or
heterocycles did not lead to inhibitor improvement, implying a pref-
erence for a substituted benzylidine ring at this part of the scaffold.
Important for potency is the para position of the benzylidine ring
with a preference for hydrophobic substituents that exploit a hydro-
phobic cavity on the enzyme for binding interactions (Fig. 6) [48].
Screening of the synthesized libraries against growing cultures of
M. tuberculosis showed that several of the compounds had in vivo
biological activity with MIC values in the range of 6–25 μg/ml. How-
ever these molecules were not strong inhibitors of CysK1 in vitro,
reﬂecting either differences in membrane permeability of these
compounds or off-target effects in vivo (Kumar, V. U. J., Poyraz, O.,
Saxena, S., Schnell, R., Yogeeswari, P., Schneider, G. and Sriram, D.,
unpublished results).e modeling, virtual screening and in vitro enzyme assays. The pharmacophore, describing
e residues, was generated using the structure of the CysK1–peptide complex as template.
ceptors/donors. The latter are indicated by the red and pink spheres. As the result of the
Table 1
Progress of the iterative structure-based inhibitor design for CysK1 fromM. tuberculosis by
pharmocophore modeling and organic synthesis.
Cycle Number of
compounds
IC50 (nM) MIC (μg/ml)
Template 1 5000 –
Round 1 232 102 –
Round 2 100 86 –
Round 3 90 19 6–25
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O-acetylserine sulfhydrylases from other pathogenic organisms
have also been targeted for inhibitor design. The crystal structure of
the complex of CysK from Haemophilus inﬂuenza with the inhibitory
decapeptide from the C-terminus of serine-acetyltransferase [23] was
used as template for the docking of 400 pentapeptides into the active
site [49]. Based on the predicted afﬁnity of these peptides fourteen
were selected for experimental determination of binding constants.
The dissociation constant for the best binder was 24.9 μM, compared
to the Kd of 44 μM for the wild-type peptide. The study highlighted
the contributions of important peptide–protein interactions to the bind-
ing afﬁnity and allowed the deﬁnition of a pharmacophore for further
design of peptidometic inhibitors.
Another approach to identify inhibitors binding to the active site of
H. inﬂuenza CysKwas based on 2-substituted-cyclopropane-1-carboxylic
acids [50]. Several derivatives of this scaffold were synthesized that
displayed dissociation constants better than 10 μM,with the best binder,
(±)-trans-2-[(1E)-prop-1-en-1-yl]cyclopropanecarboxylic acid, show-
ing a Kd of 1.5 μM. Evaluation of this compound using enzyme assays
gave an IC50 of 700 μM, displaying a signiﬁcant difference from the
determined Kd value of 1.5 μM. The absence of competition with
substrates for the active site in the determination of the Kd value was
suggested to account for this observed difference [50].Fig. 6. A: Superposition of the crystal structures of the CysK1–peptide complex, the template fo
initial hit, 3-({5-[2-(carboxymethoxy)benzylidene]-3-methyl-4-oxo-1,3-thiazolidin-2-ylidene}
compound in orange. B. Surface view of part of the structure of CysK1 in complex with the in
exploited during structure based inhibitor design. The structure of the inhibitor is shown as a sti
structure of the most potent inhibitor (IC50 of 19 nM) 3-((Z)-((Z)-5-(4-ﬂuorobenzylidene)-3
design and library synthesis. D: Chemical structure of the thiazolidine scaffold and summary o
introduced in the course of structure based inhibitor design are denoted R1–R5.In silico screening of a subset of the Zinc database was employed to
identify potential inhibitors binding to the active sites of OASS A and
OASS B from Salmonella typhimurium [51]. Dissociation constants for
the most promising hits from in silico screening/docking were found
in the range of 3–34 μM, but their ability to inhibit the enzymatic
reaction has not yet been reported. Importantly, small molecules were
identiﬁed that interact with both enzymes, with a Kd of 3 μM for OASS
A and 50 μM for OASS B.
In silico screening methods were also applied in the case of CysK
from the eukaryotic parasite Entamoeba histolytica [52] to identify active
site-directed inhibitors. Four of the best hits from the screening protocol
were selected for experimental determination of the binding constants
and gave Kd values in the range of 0.18–8 μM. Single point enzyme
assays showed inhibition of the reaction to moderate extents, but
there was no apparent correlation between Kd and inhibitory power of
the compounds, reﬂecting the non-equivalence of Kd and Ki.5. Conclusions and outlook
There is increasing evidence for bacterial de novo cysteine biosyn-
thesis being a promising drug target, but further validation usingprecise
gene knock-outs and appropriate animal models to demonstrate that
this pathway is essential for survival of the pathogen during infection
is needed. For M. tuberculosis this is a particular challenge as CysM and
CysK2 related activities/functions are expected to prevail in the persistent
phase which requires a reliable model system for latency. Granuloma are
the characteristic hallmark of human latent tuberculosis and a number of
model systems have been developed, albeit most with some deﬁciencies
in modeling human granuloma [3].
The second complicating issue in targeting cysteine biosynthesis in
M. tuberculosis is the intricate situation represented by two, if not
three viable pathways to cysteine formation. Although these might be
active in different stages of the life cycle of M. tuberculosis (activelyr the pharmacophore modeling, and the structure of the complex of CysK1 with the best
amino) benzoic acid (IC50 of 103 nM). The peptide is shown in green and the thiazolidine
itial hit illustrating the two pockets (shown in two different surface colors) which were
ckmodel and the positions of the explored substituents are indicated (R1–R5). C: Chemical
-methyl-4-oxo-thiazolidin-2-ylidene)amino)benzoic acid, developed by structure-based
f the initial structure–activity relationships (SAR). The positions where substituents were
1182 R. Schnell et al. / Biochimica et Biophysica Acta 1854 (2015) 1175–1183dividing and persistent phase, respectively) they nevertheless represent
potential back-up systems in case one of these pathways is severely
disrupted by for instance antibacterial drugs. Therefore development
of small-molecule drugs inhibiting at least two of these enzymes, either
by two compounds or, preferentially, one inhibitor targeting bothmight
be required. Given the low sequence identities between themycobacte-
rial cysteine synthases and differences in substrate speciﬁcity, the latter
is a particular challenge for medicinal chemistry. It is however promis-
ing that several of the published cysteine synthase inhibitors display
anti-bacterial activity [47], although it remains to be shown that these
inhibitors hit CysK1 also in vivo.
Compounds that are developed in the course of early drug discovery
against pathogenic bacteria are, even if they fail as lead candidates for
further drug development, potentially useful as chemical probes to
study the regulation of cysteine biosynthesis. In particular in complicated
cases such asM. tuberculosis they could provide alternative and additional
tools to selectively turn off one of these pathways and examine the
regulatory and metabolic responses of the bacterium.
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